{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:04:35Z","timestamp":1790229875885,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xops.2025.100798","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:33:52Z","timestamp":1745030032000},"page":"100798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE\/RHINE Trials"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Glittenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Holekamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100798_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s13300-017-0332-x","article-title":"Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome","volume":"8","author":"Chatziralli","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.xops.2025.100798_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6096017","article-title":"Significance of hyperreflective foci as an optical coherence tomography biomarker in retinal diseases: characterization and clinical implications","volume":"2021","author":"Fragiotta","year":"2021","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8820216","article-title":"Behavior of SD-OCT detectable hyperreflective foci in diabetic macular edema patients after therapy with anti-VEGF agents and dexamethasone implants","volume":"2021","author":"R\u00fcbsam","year":"2021","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.xops.2025.100798_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","article-title":"OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant","volume":"125","author":"Zur","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100798_bib5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","article-title":"Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema","volume":"116","author":"Bolz","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100798_bib6","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1167\/iovs.17-22725","article-title":"Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment","volume":"58","author":"Hwang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100798_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41433-020-0949-2","article-title":"Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol","volume":"35","author":"Kaya","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.100798_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/491835","article-title":"Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT","volume":"2013","author":"Vujosevic","year":"2013","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.xops.2025.100798_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/aos.13294","article-title":"Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema","volume":"95","author":"Vujosevic","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib10","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1167\/iovs.12-9950","article-title":"Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema","volume":"53","author":"Framme","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100798_bib11","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.ophtha.2010.06.019","article-title":"Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment","volume":"117","author":"Ota","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100798_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12886-022-02575-9","article-title":"Comparison of hyperreflective foci in macular edema secondary to multiple etiologies with spectral-domain optical coherence tomography: an observational study","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/IAE.0000000000001304","article-title":"Hyperreflective retinal spots in normal and diabetic eyes: B-scan and en face spectral domain optical coherence tomography evaluation","volume":"37","author":"Vujosevic","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100798_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.xops.2025.100798_bib15","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810204","article-title":"Efficacy of simultaneous VEGF-A\/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization","volume":"11","author":"Foxton","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2025.100798_bib16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.100798_bib17","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2025.100798_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910666","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"11","author":"Regula","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2025.100798_bib19","article-title":"YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale","volume":"2","author":"Eter","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2025.100798_bib20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100798_bib21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100798_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.65.5.26","article-title":"Intraretinal hyperreflective foci are almost universally present and co-localize with intraretinal fluid in diabetic macular edema","volume":"65","author":"von Schulthess","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100798_bib23","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1111\/aos.13935","article-title":"Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers","volume":"97","author":"Bonfiglio","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00592-019-01389-4","article-title":"Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema","volume":"57","author":"Cavalleri","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.xops.2025.100798_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/diagnostics10060413","article-title":"The application of structural retinal biomarkers to evaluate the effect of intravitreal ranibizumab and dexamethasone intravitreal implant on treatment of diabetic macular edema","volume":"10","author":"Ceravolo","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.xops.2025.100798_bib26","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.2147\/OPTH.S264669","article-title":"Optical coherence tomographic patterns as predictors of structural outcome after intravitreal ranibizumab in diabetic Macula edema","volume":"14","author":"Chen","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/IAE.0000000000000995","article-title":"Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema","volume":"36","author":"Kang","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100798_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12886-019-1168-0","article-title":"Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1120672120925788","article-title":"Short-term outcomes of intravitreal dexamethasone in relation to biomarkers in diabetic macular edema","volume":"31","author":"Narnaware","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib30","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","author":"Chaudhary","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib31","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.oret.2022.03.020","article-title":"Hyperreflective dots on OCT as a predictor of treatment outcome in diabetic macular edema: a systematic review","volume":"6","author":"Huang","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100798_bib32","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2147\/OPTH.S272328","article-title":"Macular vessel density in diabetic retinopathy patients: how can we accurately measure and what can it tell us?","volume":"15","author":"Pramil","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100798_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1167\/iovs.17-23042","article-title":"Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema","volume":"59","author":"Lee","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100798_bib34","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/IAE.0000000000000250","article-title":"Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography and fundus photography","volume":"34","author":"Pemp","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100798_bib35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41598-020-57646-y","article-title":"Hyperreflective foci in the outer retinal layers as a predictor of the functional efficacy of ranibizumab for diabetic macular edema","volume":"10","author":"Yoshitake","year":"2020","journal-title":"Sci Rep"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452500096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452500096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T21:09:58Z","timestamp":1772053798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266691452500096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S266691452500096X"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100798","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE\/RHINE Trials","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100798"}}